Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Henderson | Lakes | McCracken | Webster
Davis Motor Sales banner ad

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

Archaeology Field School at Land Between The Lakes

GOLDEN POND, Ky. (9/14/14) — Land Between The Lakes will host an Archaeology Field School for youth ages 10 through 13… Read More

MPD Responds to a Disturbance at Baptist Health Emergency Room

MADISONVILLE, Ky. (9/13/14) — Madisonville Police responded to a disturbance call from Baptist Health emergency room… Read More

Most Read This Week (Site-Wide)

September 12, 2014 16284

Woman's Body Found in Theater Day After…

in Top Stories by Rita Dukes Smith, SurfKY News Director
September 10, 2014 8019

BREAKING NEWS UPDATE: Police Capture…

in Top Stories by Amber Averitt, SurfKY News
September 10, 2014 4173

Hopkins, Webster Men Arrested for Meth by…

in Top Stories by Sheriff Curtis McGehee
September 10, 2014 3928

Woman Accused of Trying to Give Child…

in Top Stories by Det. Otis Chamberlain
September 13, 2014 3019

MPD Responds to a Disturbance at Baptist…

in Top Stories by Madisonville Police Department

Most Read Stories from Hopkins County

September 10, 2014 8019

BREAKING NEWS UPDATE: Police Capture…

in Top Stories by Amber Averitt, SurfKY News
September 10, 2014 3928

Woman Accused of Trying to Give Child…

in Top Stories by Det. Otis Chamberlain
September 13, 2014 3019

MPD Responds to a Disturbance at Baptist…

in Top Stories by Madisonville Police Department
September 11, 2014 2443

Suspect Arrested for Possession of…

in Top Stories by Madisonville Police Department
September 11, 2014 1942

Three Injured in Early Morning Two-Car…

in Top Stories by Officer Falon Graham

Most Read Stories from Owensboro

September 10, 2014 2134

Owensboro Police Department Activity…

in News by Dennis Beard, SurfKY News
September 10, 2014 1926

Randy Lanham, Marty Brown, Team Up for…

in Top Stories by Paul McRee, SurfKY News
September 10, 2014 1597

Owensboro Police Conduct Investigations

in News by Dennis Beard, SurfKY News
September 11, 2014 1284

Owensboro Police Department Activity…

in News by Dennis Beard, SurfKY News
September 11, 2014 1253

Owensboro Parks Plans Fall Day Camp

in News by Brittni Bunn

Most Read Stories from Muhlenberg County

September 11, 2014 2990

Subject of Officer-Involved Shooting…

in Top Stories by Rita Dukes Smith, SurfKY News Director
September 10, 2014 2860

School System's New Finance Officer Aims…

in Top Stories by Charles W. Riley II, SurfKY News
September 10, 2014 2600

School System's Request for $5.5M Falls…

in Top Stories by Charles W. Riley II, SurfKY News
September 11, 2014 2225

Two Accidents Occur on U.S. 62 Within…

in Top Stories by Trooper Stu Recke
September 11, 2014 1739

Job Corps Students Volunteer with…

in Top Stories by Karen Robinson

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)

SurfKY Owensboro News Bureau
920 Frederica St. / Suite 210  •  Owensboro, KY 42301  •  270.683-8060 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 03social 04social 22social 21social 06